Cargando…

Identification of Novel Drug Targets for the Treatment of Diabetic Retinopathy

Vision loss in diabetic retinopathy (DR) is attributable to retinal vascular disorders that result in macular edema and neoangiogenesis. In addition to laser photocoagulation therapy, intraocular injections of antivascular endothelial growth factor drugs have contributed to the treatment of these di...

Descripción completa

Detalles Bibliográficos
Autor principal: Uemura, Akiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753485/
https://www.ncbi.nlm.nih.gov/pubmed/23991398
http://dx.doi.org/10.4093/dmj.2013.37.4.217
_version_ 1782281839175532544
author Uemura, Akiyoshi
author_facet Uemura, Akiyoshi
author_sort Uemura, Akiyoshi
collection PubMed
description Vision loss in diabetic retinopathy (DR) is attributable to retinal vascular disorders that result in macular edema and neoangiogenesis. In addition to laser photocoagulation therapy, intraocular injections of antivascular endothelial growth factor drugs have contributed to the treatment of these disease conditions. Nonetheless, the clinical feasibility of intraocular drug administration has raised an increasing demand to develop alternative drugs that can fundamentally ameliorate the retinal vascular dysfunctions in DR. For this purpose, experimental animal models that reproduce human DR would be of clinical benefit. Despite the unavailability of DR models in rats or mice, pharmacological and genetic manipulations without hyperglycemia have successfully recapitulated retinal edema and neoangiogenesis in postnatal mouse retinas, thereby enabling the understanding of the pathophysiology underlying DR. This article highlights the utility of experimental mouse models of retinal vascular abnormalities and discusses cellular and molecular mechanisms responsible for the onset and progression of DR. These approaches will lead to the identification of novel drug targets for the restoration of vascular integrity and regeneration of functional capillaries in DR.
format Online
Article
Text
id pubmed-3753485
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Korean Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-37534852013-08-29 Identification of Novel Drug Targets for the Treatment of Diabetic Retinopathy Uemura, Akiyoshi Diabetes Metab J Review Vision loss in diabetic retinopathy (DR) is attributable to retinal vascular disorders that result in macular edema and neoangiogenesis. In addition to laser photocoagulation therapy, intraocular injections of antivascular endothelial growth factor drugs have contributed to the treatment of these disease conditions. Nonetheless, the clinical feasibility of intraocular drug administration has raised an increasing demand to develop alternative drugs that can fundamentally ameliorate the retinal vascular dysfunctions in DR. For this purpose, experimental animal models that reproduce human DR would be of clinical benefit. Despite the unavailability of DR models in rats or mice, pharmacological and genetic manipulations without hyperglycemia have successfully recapitulated retinal edema and neoangiogenesis in postnatal mouse retinas, thereby enabling the understanding of the pathophysiology underlying DR. This article highlights the utility of experimental mouse models of retinal vascular abnormalities and discusses cellular and molecular mechanisms responsible for the onset and progression of DR. These approaches will lead to the identification of novel drug targets for the restoration of vascular integrity and regeneration of functional capillaries in DR. Korean Diabetes Association 2013-08 2013-08-14 /pmc/articles/PMC3753485/ /pubmed/23991398 http://dx.doi.org/10.4093/dmj.2013.37.4.217 Text en Copyright © 2013 Korean Diabetes Association http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Uemura, Akiyoshi
Identification of Novel Drug Targets for the Treatment of Diabetic Retinopathy
title Identification of Novel Drug Targets for the Treatment of Diabetic Retinopathy
title_full Identification of Novel Drug Targets for the Treatment of Diabetic Retinopathy
title_fullStr Identification of Novel Drug Targets for the Treatment of Diabetic Retinopathy
title_full_unstemmed Identification of Novel Drug Targets for the Treatment of Diabetic Retinopathy
title_short Identification of Novel Drug Targets for the Treatment of Diabetic Retinopathy
title_sort identification of novel drug targets for the treatment of diabetic retinopathy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753485/
https://www.ncbi.nlm.nih.gov/pubmed/23991398
http://dx.doi.org/10.4093/dmj.2013.37.4.217
work_keys_str_mv AT uemuraakiyoshi identificationofnoveldrugtargetsforthetreatmentofdiabeticretinopathy